Results from Phase 3 MonumenTAL-3 Study at EHA 2026: Talquetamab Plus Daratumumab Showed Significant Reduction in Risk of Disease Progression in Relapsed/Refractory Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/monumental-3-study-results-eha-2026)